Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer

British Journal of Surgery

Volumn 100, Issue 11, 2013, Pages 1490-1497

  Miyata, H ^a   Yamasaki, M ^a   Takahashi, T ^a   Murakami, K ^a   Kurokawa, Y ^a   Nakajima, K ^a   Takiguchi, S ^a   Mori, M ^a   Doki, Y ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; DIAGNOSTIC AGENT;

ADJUVANT THERAPY; CARCINOMA, SQUAMOUS CELL; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; EVALUATION STUDY; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MULTIMODAL IMAGING; PROCEDURES; SCINTISCANNING; TREATMENT OUTCOME; ARTICLE; ESOPHAGUS TUMOR; METHODOLOGY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOADJUVANT THERAPY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84883467230     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9253     Document Type: Article

References (36)

1. Shimada H, Nabeya Y, Matsubara H, Okazumi S, Shiratori T, Shimizu T, et al. Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg 2006; 19: 250-254.
2. Rice TW, Zuccaro G Jr, Adelstein DJ, Rybicki LA, Blackstone EH, Goldblum JR,. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 1998; 65: 787-792.
3. Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Hölscher A, Law S, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008; 248: 979-985.
4. Rizk N, Venkatraman E, Park B, Flores R, Bains MS, Rusch V,; American Joint Committee on Cancer staging system. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 2006; 132: 1374-1381.
5. Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, et al. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg 2007; 84: 365-373.
6. Mariette C, Piessen G, Briez N, Triboulet JP,. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008; 247: 365-371.
7. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 2005; 24: 810-817.
8. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweileret E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005; 242: 684-692.
9. Dresner SM, Griffin SM,. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg 2000; 87: 1426-1433.
10. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K,. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004; 198: 205-211.
11. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-3210.
12. Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Kuwano H,. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 2004; 91: 1004-1009.
13. Ott K, Weber W, Siewert JR,. The importance of PET in the diagnosis and response evaluation of esophageal cancer. Dis Esophagus 2006; 19: 433-442.
14. Omloo JM, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW, et al. FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol 2011; 18: 3338-3352.
15. Rebollo Aguirre AC, Ramos-Font C, Villegas Portero R, Cook GJ, Llamas Elvira JM, Tabares AR,. 18F-fluorodeoxyglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature. Ann Surg 2009; 250: 247-254.
16. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065.
17. Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22: 900-908.
18. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805.
19. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, et al. 2-Fluoro-2-deoxy- d -glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004; 101: 1776-1785.
20. Mamede M, Abreu-E-Lima P, Oliva MR, Nosé V, Mamon H, Gerbaudo VH,. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol 2007; 30: 377-388.
21. Sobin L, Gospodarowicz M, Wittekind C, (eds). International Union Against Cancer (UICC): TNM Classification of Malignant Tumours (7th edn). Wiley: New York, 2009.
22. Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, et al. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol 2012; 106: 441-447.
23. Yanagawa M, Tatsumi M, Miyata H, Morii E, Tomiyama N, Watabe T, et al. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med 2012; 53: 872-880.
24. Makino T, Miyata H, Yamasaki M, Fujiwara Y, Takiguchi S, Nakajima K, et al. Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma. Surgery 2010; 148: 908-918.
25. Miller AB, Hoogstraten B, Staquet M, Winkler A,. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
26. Japanese Society for Esophageal Diseases. Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus (10th edn). Kanehara Syuppan: Tokyo, 2007.
27. Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Konishi K, et al. Prognostic value of endoscopic biopsy findings after induction chemoradiotherapy with and without surgery for esophageal cancer. Ann Surg 2011; 253: 279-284.
28. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 2006; 106: 1017-1025.
29. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD,. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008; 98: 547-557.
30. van Westreenen HL, Westerterp M, Bossuyt PM, Pruim J, Sloof GW, van Lanschot JJ, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004; 22: 3805-3812.
31. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2001; 94: 921-928.
32. Kobori O, Kirihara Y, Kosaka N, Hara T,. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 1999; 86: 1638-1648.
33. Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, Miyazaki T, et al. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 2009; 115: 3196-3203.
34. Gillies RS, Middleton MR, Han C, Marshall RE, Maynard ND, Bradley KM, et al. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma. Br J Surg 2012; 99: 239-245.
35. Hsu PK, Lin KH, Wang SJ, Huang CS, Wu YC, Hsu WH,. Preoperative positron emission tomography/computed tomography predicts advanced lymph node metastasis in esophageal squamous cell carcinoma patients. World J Surg 2011; 35: 1321-1326.
36. Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, et al. [18F]-Fluorodeoxyglucose- positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009; 250: 888-894.